Full Conference Agenda

Home / Schedule / Full Conference Agenda

Abstract Details

<< Back to Detailed Agenda

10/10/2023  |   2:45 PM - 3:45 PM   |  Courtroom

Congenital cytomegalovirus (cCMV) surveillance: a recently added threat in the Surveillance for Emerging Threats to Pregnant People and Infants Network (SET-NET)

Abstract Summary

Congenital cytomegalovirus (cCMV) is not nationally notifiable in the U.S.; however, state-level surveillance data could be used to quantify burden of disease, identify high-risk groups, and monitor trends in reporting. Findings can help inform resource allocation, early intervention, and newborn screening policy and evaluate future interventions. In 2022, CDC assessed current cCMV surveillance activities conducted by state health departments. Ten states were conducting surveillance to track cCMV cases during early infancy and provide resources and services to families. Cases were identified through targeted newborn screening (CT, UT, VA) and diagnostic codes (CO, DE, IL, MI, NJ, NY, OK). Most participating states identified <10% of expected cCMV infections annually and reported challenges in collecting data on long-term outcomes. Since the assessment, Minnesota approved the addition of cCMV to the state newborn screening panel, Florida and Maine passed legislations for targeted cCMV screening and reporting, and Kentucky passed legislation for targeted screening. As screening for cCMV expands, identifying ways to ensure integration of newborn screening with surveillance and follow-up will be important. In 2023, CDC funded five states (IA, NJ, NY, MN, and UT) to pilot cCMV surveillance within SET-NET to identify, develop, and evaluate surveillance methods. States with cCMV surveillance systems in various stages of implementation were selected for participation. New York has ascertained cases through diagnostic codes since 2016, Utah began targeted hearing screening and surveillance in 2013 followed by high-risk screening in 2019, and Minnesota implemented universal newborn screening and surveillance in 2023. This breakout session will describe recent efforts to assess and improve state-level cCMV surveillance in the U.S. The CDC will summarize cross-state findings from the first year of SET-NET pilot. Additionally, the Minnesota Department of Health will describe their efforts, including development of a surveillance case definition, inclusion and exclusion criteria, data linkages, and lessons learned.

Learning Objectives

  • Summarize the status of state-level cCMV surveillance in the United States (U.S.)
  • Describe the goals and cross-state outcomes of the cCMV surveillance pilot within SET-NET (Surveillance for Emerging Threats to Pregnant People and Infants Network)
  • Report findings from the first year of the SET-NET pilot in Minnesota

Presentation

3440589_16075AshritaRau.pdf
3440589_16075SondraRosendahl.pdf

Handouts

No handouts have been uploaded.

Presenters


Sondra Rosendahl | Co-Author

sondra.rosendahl@state.mn.us;
Sondra is a licensed genetic counselor who has been with the Minnesota Department of Health (MDH) Newborn Screening Program since 2011. Sondra is the coordinator of MDH’s Advisory Committee on Heritable and Congenital Disorders whose role is to provide advice and recommendations to the Minnesota Commissioner of Health concerning tests and treatments for disorders found in newborn children.

ASHA DISCLOSURE

Financial - Receives Grants for Other activities from Centers for Disease Control & Prevention.  

Nonfinancial - No relevant nonfinancial relationship exists.

AAA DISCLOSURE

Financial - Receives support from Centers for Disease Control & Prevention for MDH has received a cooperative grant for laboratory surveillance: Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases.  


Kristen Nichols Heitman | Co-Author

wwd6@cdc.gov;
Kelley Raines, MPH, is an epidemiologist with the Vaccine Preventable Diseases Branch in the CDC’s Division of Viral Diseases in Atlanta, GA. Her primary areas of work include the epidemiology and prevention of measles, rubella, and cytomegalovirus.

ASHA DISCLOSURE

Financial -

Nonfinancial -

AAA DISCLOSURE

Financial - No relevant financial relationship exists.


Jessica Leung | Co-Author

JLeung@cdc.gov;
Jessica Leung is an epidemiologist in the Division of Viral Diseases at the Centers for Disease Control and Prevention. She works on infectious disease surveillance, outbreak investigations, and research-related projects on viral vaccine-preventable diseases in the United States. Ms. Leung received her BA in Biochemistry and Molecular Biology from Dartmouth College and MPH in Epidemiology of Microbial Diseases from Yale University.

ASHA DISCLOSURE

Financial - No relevant financial relationship exists.

Nonfinancial - No relevant nonfinancial relationship exists.

AAA DISCLOSURE

Financial - No relevant financial relationship exists.


David Sugerman | Co-Author

ggi4@cdc.gov;
David Sugerman, M.D., M.P.H., is a medical epidemiologist and team lead with the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention. His team focused on measles, rubella, and CMV epidemiology.

ASHA DISCLOSURE

Financial -

Nonfinancial -

AAA DISCLOSURE

Financial - No relevant financial relationship exists.


Kate woodworth | Co-Author

vnt0@cdc.gov;
NA

ASHA DISCLOSURE

Financial -

Nonfinancial -

AAA DISCLOSURE

Financial - No relevant financial relationship exists.


Van Tong | Co-Author

vct2@cdc.gov;
NA

ASHA DISCLOSURE

Financial - No relevant financial relationship exists.

Nonfinancial - No relevant nonfinancial relationship exists.

AAA DISCLOSURE

Financial - No relevant financial relationship exists.


Tatiana Lanzieri | Co-Author

uyk4@cdc.gov;
Tatiana M. Lanzieri, M.D., M.P.H., is a medical epidemiologist with the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention. She has over 20 years of experience in infectious disease epidemiology, surveillance, and outbreak investigation.

ASHA DISCLOSURE

Financial - No relevant financial relationship exists.

Nonfinancial - No relevant nonfinancial relationship exists.

AAA DISCLOSURE

Financial -


Kelley Raines | POC-Point of Contact, Primary Presenter

pvw2@cdc.gov;
Kelley Raines, MPH, is an epidemiologist with the Vaccine Preventable Diseases Branch in the CDC’s Division of Viral Diseases in Atlanta, GA. Her primary areas of work include the epidemiology and prevention of measles, rubella, and cytomegalovirus.

ASHA DISCLOSURE

Financial - No relevant financial relationship exists.

Nonfinancial - No relevant nonfinancial relationship exists.

AAA DISCLOSURE

Financial - No relevant financial relationship exists.


Tory Kaye | Co-Presenter

tory.kaye@state.mn.us;
Tory is an epidemiologist in the Newborn Screening Program at the Minnesota Department of Health. She leads epidemiology for the blood spot program, analyzing the program’s pre-analytical, analytical, and post-analytical dried blood spot data to improve the lives of babies in Minnesota. She received her Bachelors of Science degree in Animal Science and her Masters of Public Health degree both from the University of Minnesota. In her spare time, Tory enjoys camping and anything else involving the outdoors, as well as spending time with her family and friends including cat, 4 turtles,2 goats, and chickens.

ASHA DISCLOSURE

Financial - No relevant financial relationship exists.

Nonfinancial - No relevant nonfinancial relationship exists.

AAA DISCLOSURE

Financial - No relevant financial relationship exists.


Ashrita Rau | Co-Presenter

tcy3@cdc.gov;
Ashrita Rau, MPH, is an epidemiologist with the Vaccine Preventable Diseases Branch in the CDC’s Division of Viral Diseases in Atlanta, GA. Her primary areas of work include the epidemiology and prevention of measles, rubella, and cytomegalovirus.

ASHA DISCLOSURE

Financial - No relevant financial relationship exists.

Nonfinancial - No relevant nonfinancial relationship exists.

AAA DISCLOSURE

Financial - No relevant financial relationship exists.